Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis

Abstract

Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE.Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were completed through AutoDock Vina and PyMOL software for visualization.Result: A total of 292 potential targets of IGU, 6501 related disease targets of SLE, and 114 cross targets were screened from the aforementioned database. Network topology analysis identified 10 hub targets, such as CASP3, AKT1, EGFR, MMP9, and IGF1. GO enrichment analysis mainly focuses on the negative regulation of the apoptotic process and signal transduction. KEGG enrichment analysis illustrated that the PI3K-AKT signaling pathway, MAPK signaling pathway, and FoxO signaling pathway might play a significant role in the pharmacological mechanisms of IGU act on SLE. Molecular docking confirmed that the IGU ligand had strong binding activity to the hub targets.Conclusion: This study based on network pharmacology and molecular docking validation preliminarily revealed the protein targets affected by IGU acting on SLE through, and explored potential therapeutic mechanism role of IGU in SLE treatment by multi pathways.

Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer

“…The molecule structure was compared with relevant literature, and its CAS number and 2D structure map were used to draw a 3D structure map on ChemDraw, resulting in an exported sdf format file. The sdf file was uploaded to PharmMapper for target prediction, and the Uniprot ID obtained was converted to Geneofficial ID on the UniProt platform 20 .…”

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

“…Based on network pharmacology and molecular docking, some studies have revealed the potential therapeutic mechanism of Iguratimod on SLE protein targets through PI3K-AKT signaling pathway, MAPK signaling pathway and FoxO signaling pathway (123). In the study of lupus kidney, Chen et al used Pristane to induce the kidney of systemic lupus erythematosus (SLE) mice.…”

Improved Antioxidant Capacity of Akebia trifoliata Fruit Inoculated Fermentation by Plantilactobacillus plantarum, Mechanism of Anti-Oxidative Stress through Network Pharmacology, Molecular Docking and Experiment Validation by HepG2 Cells

“…Based on the network analysis, two active components (glyceryl linolenate and βsitosterol) and four targets (PTGS2, CASP3, CASP8, and CASP9) were screened by phar-macology analysis for molecular docking. The simulated docking and relevant parameters are shown in Figure 7 and Table 3, in which a binding energy of less than −5 kcal•mol −1 indicated a strong binding force [49]. Based on this criterion, the binding sites on the four target proteins were all abundant for β-sitosterol to form firm bindings.…”